Consun Pharmaceutical Group Limited provided unaudited consolidated earnings guidance for the six-month period ended June 30, 2017. For the six months, the company expected increase in profit attributable to equity shareholders of the Company for the six-month period ended 30 June 2017 as compared with that for the six-month period ended 30 June 2016, which was mainly attributable to the increases in sales of Uremic Clearance Granules and women and children products and the consolidation of the operating results of Guangxi Yulin Pharmaceutical Group Limited during the period.